Efficacy of endoluminal interventional therapy in diabetic peripheral arterial occlusive disease: a retrospective trial by Xiao, Liang et al.
ORIGINAL INVESTIGATION Open Access
Efficacy of endoluminal interventional therapy in
diabetic peripheral arterial occlusive disease: a
retrospective trial
Liang Xiao
1*, De-sheng Huang
2, Jia-jie Tong
1 and Jing Shen
1
Abstract
Background: The purpose of this study was to assess the efficacy of interventional therapy for peripheral arterial
occlusive disease and the difference between diabetic patients and non-diabetic patients.
Methods: 139 consecutive patients between September 2006 and September 2010 who underwent percutaneous
lower extremity revascularization for arterial lesions were divided into diabetes group (n = 62) and non-diabetes
group (n = 77). Before intervention, rest ankle brachial indexes and three dimensional computed tomography
angiography from abdominal aorta to tiptoe were performed. The interventional treatments included angioplasty
with or without stenting. The clinical outcomes included rest ankle-brachial indexes, primary patency rates,
secondary patency rates and limb-salvage rates for 6-month, 12-month, 24-month and 36-month after treatment.
The primary and secondary patency rates of all interventions and the limb-salvage rates of the patients are
illustrated by Kaplan-Meier curves and compared by log-rank analysis.
Results: The interventional operation success rates were 98.4% (61/62) in diabetes group and 100% (77/77) in non-
diabetes group. The re-interventional operation success rates were 85.7% (18/21) in diabetes group and 76.9% (20/
26) in non-diabetes group. The mean value of ankle brachial indexes was significantly increased after intervention
(0.397 ± 0.125 versus 0.779 ± 0.137, t = -25.780, P < 0.001) in diabetes group and (0.406 ± 0.101 versus 0.786 ±
0.121, t = -37.221, P < 0.001) in non-diabetes group. Perioperative 30-day mortality was 0%. Major complications
included groin hematoma in 7.2%, and pseudoaneurysm formation 2.2%. In diabetes group, 6, 12, 24, and 36-
month primary patency rates were 88.7% ± 4.0%, 62.3% ± 6.6%, 55.3% ± 7.0%, and 46.5% ± 7.5%; secondary
patency rates were 93.5% ± 3.1%, 82.3% ± 5.1%, 70.8% ± 6.5%, and 65.7% ± 7%; limb-salvage rates were 95.2% ±
2.7%, 87.7% ± 4.4%, 85.5% ± 4.8%, and 81.9% ± 5.8%. In non-diabetes group, 6, 12, 24, and 36-month primary
patency rates were 90.9% ± 3.3%, 71.8% ± 5.4%, 71.8% ± 5.4%, and 60.9% ± 6.2%; secondary patency rates were
96.1% ± 2.2%, 91.6% ± 3.3%, 82.7% ± 4.8%, and 71.8% ± 6.2%; limb-salvage rates were 97.4% ± 1.8%, 94.4% ± 2.7%,
90.6% ± 3.7%, and 83.1% ± 5.4%. The differences between two groups were not significant (P > 0.05).
Conclusion: With a low risk of morbidity and mortality, the percutaneous revascularization accepted by patients
does not affect ultimate necessary surgical revascularization and consequently should be considered as the
preferred therapy for chronic lower extremity ischemia. The efficacy and prognosis of interventional therapy in
diabetic patients is similar that in non-diabetic patients.
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Diabetes is a common concomitant condition for the
patients with peripheral arterial occlusive disease
(PAOD) and is increasing in prevalence [1]. Diabetics
with PAOD carry a considerably worse prognosis than
those without diabetes [2]. They account for more than
half in the non-traumatic lower limb amputations. 20%
of these patients with infected foot wounds ended up
with some type of lower extremity amputation.
Previously, percutaneous lower extremity arterial
revascularization was offered only to the patients who
had contraindications to open surgical bypass or had
used up all surgical options. In recent years, however,
an increasing number of patients have undergone percu-
taneous intervention as a first-line therapy for arterial
occlusive disease of the lower extremity [3]. Successful
revascularization could reduce the rate of major ampu-
tation, improve the healing of foot ulcers and raise the
quality of life in diabetic patients with PAOD. Further-
more, an increasing number of techniques for percuta-
neous therapy have become available, including laser
angioplasty, drug eluting balloon, absorbable metal stent
and rotational atherectomy [4-8], thereby expanding the
range and type of lesions suitable for percutaneous
treatment.
In the study we sought to evaluate lower extremity
arterial interventional therapy feasibility, revasculariza-
tion efficacy, complications and limb salvage rate in a
population of consecutive diabetic patients and non-dia-
betic patients hospitalized for PAOD.
Materials and methods
A retrospective research of the institutional database
was performed to identify 68 diabetic patients (diabetes
group) and 80 non-diabetic patients (non-diabetes
group) between September 2006 and September 2010
who underwent percutaneous revascularization for lower
extremity arterial lesions (both stenoses and occlusions).
After a complete description of the study to the patients,
the written informed consent was obtained in accor-
dance with National Health and Medical Research
Council guidelines. The study has been approved by the
Ethics Committee of Hospital. Before intervention, rest
ankle brachial indexes (ABI) and three dimensional
computed tomography angiography (3D-CTA) from
abdominal aorta to tiptoe were performed in all patients.
Indications for interventional procedure included debili-
tating claudication or limb-threatening ischemia and
lower extremity arterial lesions found by 3D-CTA.
A contralateral femoral approach was used in the
majority of patients while an ipsilateral antegrade femoral
approach was only employed when isolated tibial arterial
disease was anticipated from preoperative studies.
Interventional operations were performed through a 5 F
or 6 F sheath (length 11-45 cm). Selective angiography
was performed to localize lesions and measure the range
of lesions by using 4 F or 5 F catheter. The decision to
intervene was made after diagnostic angiography. Decid-
ing whether to proceed with revascularization operation
was based on the necessity of clinical symptoms instead
of the extent of the collateralization. All patients were
anticoagulated with intravenous unfraction heparin
(5,000 units) before lesion being crossed.
Under monitoring with X-ray, lesions were crossed
with either luminal or subintimal technique using
hydrophilic guide wires (0.035, 0.018 or 0.014 inch).
Guide wires were supported using 4 F or 5 F angled
catheter. Reentry into the arterial luminal space beyond
the occlusive lesion was confirmed by angiography
before further intervention. Percutaneous transluminal
angioplasty (PTA) was performed with appropriately
sized noncompliant balloons (2.5-8.0 mm diameter) for
the treated vessel, with inflation times ranging from 60
to 180 seconds at 6 to 15 atmosphere of pressure. Stent
was implanted selectively for > 30% residual stenosis or
flow-limiting dissections. Re-examination angiography
with evaluation of the extent of residual stenosis and
distal runoff was performed after interventions. PTA
success was defined as dilation of all arterial lesions
with a residual stenosis of ≤20%. Stent technical success
was defined as a residual stenosis of < 20% after stent
placement. All interventional procedures were per-
formed under local anesthesia.
After arterial intervention, patients received 0.4 ml low
molecular heparin injection at twice daily for a week.
Activated clotting times were not monitored. Aspirin
100 mg was administered daily to all patients postopera-
tively unless contraindicated. For patients undergoing
stent placement, a loading dose of Clopidogrel 300 mg
was administered in ward, followed by 75 mg/d for 1
year. ABI was obtained one week after the procedure.
Patients were evaluated postoperatively and then at 6-
month intervals by physical examination (pulses and
presence or absence of claudication or rest pain) and by
vascular laboratory exam (ABI and arterial duplex ultra-
sound). Patency was determined primarily by arterial
duplex of the treated vessel and secondarily by ABI and
clinical parameters. Loss of patency on arterial duplex
was defined as the presence of an occlusion or a reste-
nosis associated with a velocity ratio of greater than 4:1
(relative to the segment proximal to the treated region).
Percutaneous treatment failure was defined as loss of
patency by anatomic or hemodynamic measures without
effective revascularization. During follow-up a patient
was considered to lose patency if restenosis or occlusion
was detected in any of the lesions treated.
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age for Social Sciences, version 11.5 (SPSS). Continuous
variables were described with summary statistics such as
means and standard deviations. Categorical variables
were described with frequencies and percentages. Stu-
dent’s t test and chi square analysis were used as appro-
priate to evaluate between-group differences in baseline
characteristics, and changes of ABI before and after pri-
mary intervention. Primary and secondary patency and
limb salvage rates were computed by Kaplan-Meier sur-
vival curves and compared by log-rank analysis. The dif-
ference was considered statistically significant at p <
0.05.
Results
148 patients were enrolled in the trial. 9 patients were
withdrawn from the study because of lost in follow-up.
This led to 139 (93.9%) patients who were included in
the study. The two groups did not differ significantly in
demographic or clinical characteristics and baseline ABI
(Table 1).
The mean values of ABI were significantly increased
after primary intervention (0.397 ± 0.125 versus 0.779 ±
0.137, t = -25.780, P <0 . 0 0 1 )i nd i a b e t e sg r o u pa n d
(0.406 ± 0.101 versus 0.786 ± 0.121, t = -37.221, P <
0.001) in non-diabetes group.
Primary and secondary patency rates for all interven-
tions and limb-salvage rates for patients are illustrated by
Kaplan-Meier curves (Figures 1, 2 and 3 and Table 2).
In diabetes group, 6, 12, 24, and 36-month primary
patency rates were 88.7% ± 4.0%, 62.3% ± 6.6%, 55.3% ±
7.0%, and 46.5% ± 7.5%; whereas secondary patency
rates were 93.5% ± 3.1%, 82.3% ± 5.1%, 70.8% ± 6.5%,
and 65.7% ± 7%; limb-salvage rates were 95.2% ± 2.7%,
87.7% ± 4.4%, 85.5% ± 4.8%, and 81.9% ± 5.8%. In non-
diabetes group, 6, 12, 24, and 36-month primary patency
rates were 90.9% ± 3.3%, 71.8% ± 5.4%, 71.8% ± 5.4%,
and 60.9% ± 6.2%; secondary patency rates were 96.1%
± 2.2%, 91.6% ± 3.3%, 82.7% ± 4.8%, and 71.8% ± 6.2%;
limb-salvage rates were 97.4% ± 1.8%, 94.4% ± 2.7%,
90.6% ± 3.7%, and 83.1% ± 5.4%. The differences
between two groups were not significant (P > 0.05).
A total of 83 percutaneous interventions (32 PTA
o n l y ,5 1P T Aa n dS t e n t )i n c l u d e d6 2p r i m a r yi n t e r v e n -
tions and 21 re-interventions were performed on 62 dia-
betic patients. 103 percutaneous interventions (39 PTA
o n l y ,6 4P T Aa n dS t e n t )i n c l u d e d7 7p r i m a r yi n t e r v e n -
tions and 26 re-interventions were performed on 77
non-diabetic patients. All lesions were categorized by
location: 58 were iliac lesions (23.5%)(Figure 4), 112
were femoral lesions (45.3%)(Figure 4), 42 were popliteal
lesions (17.0%)(Figure 5) and 35 were tibial lesions
(14.2%)(Figure 6). 6, 12, 24, and 36-month primary and
secondary patency rates for different lesions in diabetes
group and non-diabetes group are illustrated by Kaplan-
M e i e rc u r v e s( F i g u r e s7 ,8 ,9a n d1 0a n dT a b l e s3a n d
4).
Interventional operation success rate in diabetes group
is 98.4% (61/62). In one patient with PAOD (1.6%),
t h e r ew a sf a i l u r et oc r o s st h et o t a lo c c l u s i o nw i t ha
wire. The patient’s condition was not worsened by the
attempted intervention. The patient had successful distal
bypass. Interventional operation success rate in non-dia-
betes group is 100% (77/77).
Table 1 Demographic and Clinical Characteristics of 139 patients Across Treatment Groups at Baseline
Characteristics Diabetes group
(n = 62)
Non-diabetes group (n = 77) Test
Statistics
P
Value
Age(years) 64.7 ± 11.0 65.2 ±9.8 -0.308 0.759
Male 37(59.7%) 49(63.6%) 0.228 0.633
history of tobacco 33(53.2%) 45 (58.4%) 0.379 0.538
hypertension 36(58.1%) 53 (68.8%) 1.729 0.189
coronary artery disease 19(30.6%) 21 (27.3%) 0.191 0.662
Treatment with insulin 45 (72.6%) 0 (0%) Fisher’s
exact test
0.000
Pre-operation ABI 0.396 ± 0.125 0.406 ± 0.101 0.113 0.910
Lesion location
Iliac artery 26(23.2%) 32(23.7%) 0.002 0.964
Femoral artery 51(45.5%) 61 (45.2%) 0.202 0.653
Popliteal artery 19(17%) 23(17%) 0.010 0.921
Tibial artery 16(14.3%) 19(14.1%) 0.023 0.879
Clinical symptom
claudication 14 (22.6%) 12(15.6%) 1.106 0.293
rest pain 25 (40.3%) 33(42.9%) 0.091 0.763
gangrene or tissue loss 23 (37.1%) 32(41.5%) 0.286 0.593
Abbreviations: ABI, ankle brachial indexes
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cations were access-related and included groin hema-
toma in 7.2% patients (all not requiring operative
exploration), and pseudoaneurysm formation in 2.2%
patients (successfully treated by local pressure
bandaging).
Mean follow-up time for all patients was 26.3 ± 15.2
months (6-48 months). 47 patients accepted re-interven-
tional operation after restenosis, with success rate 80.9%
(38/47). The overall rate of percutaneous re-intervention
during the follow-up period was 33.8% (47/139). After
failure of percutaneous therapy or restenosis, 21 patients
with limb-threat underwent surgical bypass for limb-sal-
vage with success rate 76.2% (16/21), and 19 patients
underwent lower extremity major amputation.
Discussion
Etiology and prognosis
The hyperglycemia and lipid metabolic abnormality not
only lead to injury of the vascular endothelial cells, but
also initiate and promote the process of atherosclerosis
in diabetes. Some protective cytokines, such as adipo-
nectin and osteoprotegerin, could relieve the progression
of PAOD. Adiponectin exhibits anti-inflammatory and
atheroprotective actions and osteoprotegerin protects
vascular endothelial cells and inhibits atherosclerosis.
Lower plasma levels of adiponectin and higher osteopro-
tegerin were found in diabetic patients with PAOD
[9-11]. In fact, the incidence of atherosclerosis in dia-
betes was significantly higher than that in non-diabetic
patients, and the lesion in diabetes was more serious
and diffuse. For diabetes, atherosclerosis usually involved
the below-knee arteries; the severe vascular lesions and
their wide range often lead to less effective intervention;
on the other hand, initial hyperplasia or smooth muscle
cell proliferation and the progression of atherosclerosis
was more serious in diabetes than that in non-diabetes
after revascularization.
Patients with PAOD have a poor clinical course. Dur-
ing the first year of diagnosis, mortality is 20%-30%, and
an equivalent number undergo amputations or suffer
from persistent pain [12]. Lower extremity bypass has
been applied very successfully even in difficult clinical
cases, including the treatment of patients with diabetic
foot gangrene and other conditions which carry a high
risk of amputation [13]. But bypass surgery can only be
Figure 1 Primary patency rates of two groups.
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runoff, advanced age, and cardiac co-morbidities. Surgi-
cal treatment is often withheld from those patients who
would benefit. Surgical complications include death
(1.3%-6%), myocardial infarction (1.9%-3.4%), wound
infections (10%-30%), leg edema (50%-100%), and early
graft failure rates (6%-49%) requiring repeat surgery
[12,14].
Therapeutic regimen
Angioplasty for critical limb ischemia was reported
nearly 50 years ago [15]. Hanna et al. [16] reported a
21% procedural complication rate, including emboliza-
tion and thrombosis in patients with critical limb ische-
mia undergoing balloon angioplasty, whereas Dorros et
al. [17] demonstrated that PTA of below-knee arteries
could be performed with relative safety and with satis-
factory results.
The mortality and major morbidity in patients treated
for limb-threatening disease with percutaneous interven-
tions was only 0 and 8.1%, respectively, compared with
usual mortalities and morbidities of 5% and 30% for
open surgical bypass [12]. To some extent, it appears
that the short-term advantages of minimally invasive
vascular therapies are often counterbalanced by dimin-
ished durability. Percutaneous therapy for limb-threaten-
ing lower extremity vascular disease with or without
diabetes has no exception, with primary patency rates at
36 months of 46.5% and 60.9%. However, secondary
patency rates were more reasonable at 65.7% and 71.8%,
and more importantly, limb salvages rates were 81.9%
and 83.1% at 36 months.
Efficacy of different studies
It was confirmed that PTA was an effective and safe
therapy for short iliac arterial stenosis. But the long-
term patency rates of PTA in complicated iliac arterial
lesions such as long occlusion were relative low. The 3-
year primary patency rates in PTA group were lower
than 60% [18,19]; whereas primary patency rates in
stenting group were up to 90% [20-22]. Bosch and
Hunink [23] reported the technical success rate of inter-
ventional therapy for iliac occlusive disease in stent
group was higher than that in PTA group, but the dif-
ference was not statistically significant. In our study, 1-
year and 3-year primary patency rate for iliac arterial
lesions in diabetes group or non-diabetes group were
87.5%, 75.1% and 86.5%, 71.1%, respectively.
Bakken et al. [24] reported the clinical results of inter-
ventional therapy for femoral lesions with diabetes was
better than that without diabetes. In our study, 1, 3
years primary patency rate for femoral lesions in with or
without diabetes group were similar (73.2%, 58.6% and
80.9%, 52.8%). Role of femoral arterial stents in the
Figure 2 Secondary patency rates of two groups.
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meta-analysis [25] which included 452 patients who
underwent femoropopliteal PTA and 482 patients who
underwent femoropopliteal stenting, the 1-year primary
patency rates following PTA ranged from 45% to 84.2%
and at 2 years it varied from 25% to 77.2%, the 1-year
primary patency rates in the stent implantation group
varing from 63% to 90%, and 2-year primary patency
ranging from 46% to 87%. In 73 patients with average 8
cm long femoral arterial stenosis or occlusion, restenosis
rates in the stent and PTA groups were 2.9% versus
18.9%, 18.2% versus 50.0%, and 34.4% versus 61.1% at 3,
6, and 12 months by sonography [26]. Perrio et al. [27]
reported 1 year femoral artery primary patency rates
were 57% in stent group and 53% in PTA group. Kou-
gias et al. [28] reported at 1 year femoral artery primary
patency for the subintimal balloon angioplasty and sub-
intimal placement of covered stent groups was 28% ver-
sus 75%, whereas secondary patency was 37% versus
84%. But in other study undergoing subintimal angio-
plasty in the femoral and popliteal arteries, one-year pri-
mary and secondary patency for stent vs. no-stent group
Figure 3 Limb-salvage rates of two groups.
Table 2 The results of primary, secondary patency rates and limb-salvage rates for all patients
6 months 12 months 24 months 36 months
Primary Diabetic (n = 62) 88.7% ± 4.0% 62.3% ± 6.6% 55.3% ± 7.0% 46.5% ± 7.5%
patency
rate
Non-diabetic (n = 77) 90.9% ± 3.3% 71.8% ± 5.4% 71.8% ± 5.4% 60.9% ± 6.2%
Secondary Diabetic (n = 62) 93.5% ± 3.1% 82.3% ± 5.1% 70.8% ± 6.5% 65.7% ± 7.0%
patency
rate
Non-diabetic (n = 77) 96.1% ± 2.2% 91.6% ± 3.3% 82.7% ± 4.8% 71.8% ± 6.2%
Limb-salvage Diabetic (n = 62) 95.2% ± 2.7% 87.7% ± 4.4% 85.5% ± 4.8% 81.9% ± 5.8%
rate Non-diabetic (n = 77) 97.4% ± 1.8% 94.4% ± 2.7% 90.6% ± 3.7% 83.1% ± 5.4%
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Page 6 of 11was 50% versus 45% and 70% versus 78% [29]. In a con-
trast study between selective stenting and systematic
stenting of femoral artery, Becquemin et al. [30]
reported at 1-year follow-up restenosis of the treated
site was noted in 32.3% patients in selective stent group
and 34.7% patients in systematic stent group. After 4
years, limb-salvage rates in selective stent group and in
systematic stent group were 57%, 44%, respectively. Sys-
tematic stenting in femoral artery did not improve long
term patency.
The treatment of infra-popliteal arterial occlusive dis-
ease was still a clinical puzzle for vascular surgeons and
interventional radiologists. The first reason was that
infra-popliteal arterial occlusive disease usually comor-
bided with diabetic arteriosclerosis which have more cal-
cification and more hard plaque. The second reason was
that the outflow tract of infra-popliteal artery has higher
resistance. In a meta analysis, Romiti et al. [31] reported
the immediate technique success rate of PTA in infra-
popliteal arterial occlusive disease was 89%. After 12
and 36 months primary patency rates, secondary
patency rates, and limb salvage rates were 77.4% and
48.6%, 83.3% and 62.9%, 93.4%a n d8 2 . 4 % ,r e s p e c t i v e l y .
Lejay et al. [32] reported at 1 year the infra-popliteal
arteries primary patency rates and limb salvage rates for
PTA were 60% and 85%, respectively. In a contrast
study between PTA and atherectomy of infra-popliteal
arterial occlusive disease, Semaan et al. [33] reported
primary patency of the popliteal artery at 12 months
were 75% and 73%, respectivel y ,b u tt h ed i f f e r e n c ew a s
not statistically significant. In our study, 6, 12 months
primary patency rate for tibial arterial lesions with or
without diabetes were 75%, 53.8% and 73.7%, 55.3%.
The result was lower than the result in literature. 26
patients (26/35) in the study comorbided with proximal
arterial occlusive lesions may be the origin.
Limitations
This was a single-center, consecutive patient trial. ABIs
were obtained before intervention to evaluate
Figure 4 Iliaco-femoral arterial long occlusion. (a) DSA displayed
right iliac artery overall occlusion; (b) after PTA and stenting, blood
flow in right iliac artery was recovered; (c) DSA displayed right
superficial femoral artery overall occlusion; (d) after PTA and
stenting, blood flow in right superficial femoral artery was
recovered.
Figure 5 Popliteal arterial long occlusion case. (a) DSA displayed
left popliteal artery overall occlusion; (b) after PTA and stenting,
blood flow in left popliteal artery was recovered.
Figure 6 Anterior tibial artery long occlusion case. (a) DSA
displayed left anterior tibial artery long occlusion; (b-e) Deep
balloon (2.5 mm × 80 mm) dilated the anterior tibial artery; (f) after
PTA, blood flow in left anterior tibial artery was recovered.
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Figure 8 Primary, secondary patency rates for femoral lesions in two groups.
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Page 8 of 11hemodynamic impairment and at one week after inter-
vention to measure improvement. ABI value responded
objectively to the status of blood supply in lower extre-
mity, but the mickle factors influenced its magnitude. In
the condition of profuse collateral circulation in lower
extremity, ABI value could exactly respond to the extent
of vascular flow in treated position. The sample number
of this study is relative deficient, and subgroups divided
Figure 9 Primary, secondary patency rates for popliteal lesions in two groups.
Figure 10 Primary, secondary patency rates for tibial lesions in two groups.
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for contrasting with literature. As the follow-up period
was relative short, this study could not illuminate the
long term patency of interventional therapy for PAOD.
Conclusion
Percutaneous revascularization has rapidly emerged as
an alternative to open surgical bypass for patients with
chronic lower extremity ischemia. In this study, the
good short-term patency rate of percutaneous interven-
tion makes 81.9% diabetic PAOD patients and 83.1%
non-diabetic PAOD patients keep the limb within three
years. With a low risk of morbidity and mortality, the
percutaneous revascularization accepted by patients
does not affect ultimate necessary surgical revasculariza-
tion and consequently should be considered as the pre-
ferred therapy for chronic lower extremity ischemia.
The efficacy and prognosis of interventional therapy in
diabetic patients is similar that in non-diabetic patients.
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Table 3 The results of primary and secondary patency rates for different lesions in diabetes group
6 months 12 months 24 months 36 months
iliac lesions (n = 26) primary patency rate 100% 87.5% ± 6.8% 82.6% ± 7.9% 75.1% ± 10.2%
secondary patency rate 100% 95.8% ± 4.1% 90.8% ± 6.2% 82.5% ± 9.7%
femoral primary patency rate 88.2% ± 4.5% 73.2% ± 6.4% 67.7% ± 7% 58.6% ± 8.6%
lesions
(n = 51)
secondary patency rate 94.1% ± 3.3% 89.8% ± 4.3% 84.5% ± 5.5% 73.2% ± 7.8%
popliteal primary patency rate 78.9% ± 9.4% 42.1% ± 11.3% 42.1% ± 11.3% 42.1% ± 11.3%
lesions
(n = 19)
secondary patency rate 84.2% ± 8.4% 73.7% ± 10.1% 62.7% ± 11.2% 55.8% ± 11.9%
tibial primary patency rate 75.0% ± 10.8% 53.8% ± 12.9% 30.8% ± 12.5% 30.8% ± 12.5%
lesions
(n = 16)
secondary patency rate 87.5% ± 8.3% 67.3% ± 12% 43.6% ± 13.6% 43.6% ± 13.6%
Table 4 The results of primary and secondary patency rates for different lesions in non-diabetes group
6 months 12 months 24 months 36 months
iliac lesions (n = 32) primary patency rate 96.9% ± 3.1% 86.5% ± 6.3% 77.5% ± 8.3% 71.1% ± 9.8%
secondary patency rate 100% ± 0% 100% ± 0% 90.3% ± 6.5% 83% ± 5.7%
femoral lesions primary patency rate 93.4% ± 3.2% 80.9% ± 5.2% 73.9% ± 6.1% 52.8% ± 8.6%
(n = 61) secondary patency rate 95.1% ± 2.8% 93.3% ± 3.2% 88.7% ± 4.4% 83% ± 5.7%
popliteal primary patency rate 82.6% ± 7.9% 63.2% ± 10.4% 47.7% ± 11.1% 39.8% ± 11.7%
lesions
(n = 23)
secondary patency rate 100% ± 0% 90.5% ± 6.4% 75.9% ± 9.4% 56.9% ± 11.8%
tibial primary patency rate 73.7% ± 10.1% 55.3% ± 11.9% 34.5% ± 12% 34.5% ± 12%
lesions
(n = 19)
secondary patency rate 89.5% ± 7% 71.6% ± 10.8% 57.8% ± 12.4% 38.6% ± 13.9%
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